Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pavel Jindra is active.

Publication


Featured researches published by Pavel Jindra.


Journal of Cutaneous Pathology | 2006

Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman

Ludmila Boudova; Dmitry V. Kazakov; Pavel Jindra; Radek Sima; Tomas Vanecek; Vilem Kuntscher; Vozobulova Vera; Jiri Bouda; Michal Michal

Background:  Cutaneous lymphomas co‐expressing CD56 and CD30 are very rare. They share a clinicopathological overlap with natural killer‐ (NK)/T‐cell lymphomas and anaplastic large‐cell lymphomas (ALCLs), two entities with widely disparate clinical behavior.


Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia | 2013

In vitro testing of immunosupressive effects of mesenchymal stromal cells on lymphocytes stimulated with alloantigens

Daniel Lysák; Tomas Vlas; Monika Holubová; Michaela Miklikova; Pavel Jindra

AIMS Mesenchymal stromal cells (MSC) derived from adult bone marrow or adipose tissue offer the potential to open a new frontier in medicine. MSC are involved in modulating immune response and tissue repair in vitro and in vivo. Experimental evidence and preliminary clinical studies have demonstrated that MSC exhibit an important immunomodulatory function in patients with graft versus host disease (GVHD) following allogeneic hematopoietic stem cell transplantation. The immunosuppressive properties of MSC have already been exploited in the clinical setting. However the precise mechanisms are being still investigated. METHODS We examined the immunosuppressive function of MSC by coculturing them with stimulated HLA incompatible allogeneic lymphocytes in a mixed lymphocyte culture test. The metabolic and proliferative activity of lymphocytes was determined by MTT test. RESULTS After stimulation with alloantigens the presence of MSC caused significant decrease of absorbance levels by 62% (P<0.01), 26% (P<0.01) and 6% (P=0.0437) in comparison to positive control depending on the MSC/lymphocyte ratio (1:5, 1:50, 1:500). The mitogenic stimulation of lymphocytes with fMLP or PHA was also significantly reduced during MSC cocultivation. The absorbance was reduced by 42% (P<0.001) and 67% (P<0.001). CONCLUSIONS Allogeneic bone marrow is an ideal source of MSC for clinical application. The experiments confirmed the dose-dependent inhibitory effect of MSC on lymphocyte proliferation triggered by cellular or mitogenic stimulation. The mixed lymphocyte culture test offers a simple method for characterization and verification of the immunosuppressive potential of MSC, being prepared for clinical use.


Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti | 2013

[The clinical, histopathological and imaging methods characteristics of Non-Hodgkin lymphomas in patients with brain involvement].

Samuel Vokurka; Radek Tupý; Ludmila Boudova; Jan Mraček; Pavel Jindra; Jiří Ferda; Marcela Hrabětová


Medicína pro praxi | 2018

Nejběžnější typy anémií – diagnostika, klasifikace a léčba

Kateřina Steinerová; Daniel Lysák; Pavel Jindra


Transfuze a hematologie dnes | 2016

Allogeneic hematopoietic cell transplantation in patients withFLT3-ITD mutated AML: transplantation in 1st CR is the decisivefactor for good outcome.

Pavel Jindra; Michal Karas; Tomáš Szotkowski; Daniel Lysák; Luděk Raida; Alexandra Jungová; Adam Kuba; Marcela Hrabětová; C Martin; Kateřina Steinerová


Archive | 2016

Comparison of double transplantation– tandem transplantation ortransplantation in relapse – in patients with multiple myeloma

Alexandra Jungová; Samuel Vokurka; Miroslava Schützová; Lekaa Mohammadova; Kateřina Steinerová; Daniel Lysák; Pavel Jindra; Michal Karas


Archive | 2016

Cutaneous thrombosis related to paroxysmal nocturnalhemoglobinuria relapsed after unrelated stem celltransplantation: case report.

Kateřina Steinerová; Daniel Lysák; Michal Karas; Marcela Hrabětová; Pavel Jindra


Archive | 2016

Outcome of allogeneic hematopoietic stem cell transplantationin normal karyotype AML with NPM1 mutation in kompleteremission is not affected by FLT3/ITD positivity – potentiallycrucial importace of pre-transplant level of minimal residualdisease.

Michal Karas; Kateřina Steinerová; Daniel Lysák; Marcela Hrabětová; Alexandra Jungová; Pavel Jindra


Klinická onkologie | 2016

Indikace radioterapie u pacientů s hematologickými malignitami v průběhu pěti let provozu modernizovaného centra Onkologické a radioterapeutické kliniky v Plzni.

Samuel Vokurka; Mha MUDr. Jindřich Fínek; Tomáš Svoboda; Radovan Vojtíšek; Marie Votavová; Karel Havránek; Jiří Salvét; Blanka Šindelářová; Jan Mařan; Emília Sukovská; Krasimir Vasilev; Miroslava Schützová; Věra Vozobulová; Pavel Jindra; Josef Sýkora


Archive | 2015

Allogeneic stem-cell transplantation for Hodgkin lymphoma single-center experience

Lekaa Mohammadova; Pavel Jindra; Kateřina Steinerová

Collaboration


Dive into the Pavel Jindra's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel Lysák

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Samuel Vokurka

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Michal Karas

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Alexandra Jungová

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Vladimír Koza

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ludmila Boudova

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Monika Holubová

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Dmitry V. Kazakov

Charles University in Prague

View shared research outputs
Researchain Logo
Decentralizing Knowledge